PHILADELPHIA, June 3, 2011 /PRNewswire/ — Echo Therapeutics,
Inc. (OTCBB: ECTE), a company developing its needle-free
Symphony™ tCGM System as a non-invasive, wireless,
transdermal continuous glucose monitoring system and its
Prelude™ SkinPrep System for transdermal drug delivery, today
announced that Patrick T. Mooney, M.D., CEO, President and Chairman
of the Board of Echo Therapeutics will present at the Jefferies
2011 Global Healthcare Conference.
Dr. Mooney will make a corporate presentation to prospective
corporate partners and investors on Wednesday, June 8th at 8:30 AM
ET in New York City.
About Echo TherapeuticsEcho is developing the Symphony tCGM
System as a non-invasive, wireless, transdermal continuous glucose
monitoring system for patients with diabetes and for use in
hospital critical care units. Echo is also developing its
needle-free Prelude SkinPrep System as a platform technology for
enhanced skin permeation for delivery of topical pharmaceuticals.
For More Information:Patrick T. Mooney, M.D.
Media: Richard SternChairman and Chief Executive
Officer
Stern & Co.(215) 717-4100
(212) 888-0044
‘/>”/>
![The SNAP test detects concussions in 90 seconds [Photo courtesy of Oculogica]](https://www.medicaldesignandoutsourcing.com/wp-content/uploads/2026/10/Oculogica-SNAP-268x170.jpg)
